Tinzaparin versus dalteparin for periprocedure prophylaxis of thromboembolic events in hemodialysis patients: A randomized trial

American Journal of Kidney Diseases

Volumn 60, Issue 3, 2012, Pages 427-434

  Rodger, Marc A ^a   Ramsay, Tim ^a   MacKinnon, Martin ^a   Westphal, Margit ^a   Wells, Philip S ^a   McCormick, Brendan ^a   Knoll, Greg ^a  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

Author keywords

anti Xa; dialysis; invasive procedure; Low molecular weight heparin; warfarin

Indexed keywords

DALTEPARIN; HEPARIN; TINZAPARIN; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTERIOVENOUS FISTULA; ARTICLE; BLEEDING; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG WITHDRAWAL; FEMALE; HEMODIALYSIS PATIENT; HUMAN; MALE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; OPEN STUDY; RANDOMIZED CONTROLLED TRIAL; SAMPLE SIZE; THROMBOEMBOLISM; UPPER EXTREMITY DEEP VEIN THROMBOSIS;

AGED; AGED, 80 AND OVER; DALTEPARIN; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG TOXICITY; FEMALE; FOLLOW-UP STUDIES; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INJECTIONS, SUBCUTANEOUS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PREOPERATIVE CARE; PRIMARY PREVENTION; PROSPECTIVE STUDIES; RENAL DIALYSIS; RISK ASSESSMENT; STATISTICS, NONPARAMETRIC; SURGICAL PROCEDURES, OPERATIVE; THROMBOEMBOLISM; TREATMENT OUTCOME;

EID: 84865683058     PISSN: 02726386     EISSN: 15236838     Source Type: Journal    
DOI: 10.1053/j.ajkd.2012.01.020     Document Type: Article

References (32)

1. S. Sonawane, N. Kasbekar, J.S. Berns The safety of heparins in end-stage renal disease Semin Dial 19 2006 305 310
2. J. Hirsh, R. Raschke Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy Chest 126 2004 188S 203S
3. A. Davenport Low-molecular-weight heparin for routine hemodialysis Hemodial Int 12 suppl 2 2008 S34 S37
4. W. Lim Low-molecular-weight heparin in patients with chronic renal insufficiency Intern Emerg Med 3 2008 319 323
5. M.K. Gould, A.D. Dembitzer, R.L. Doyle, T.J. Hastie, A.M. Garber Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis A meta-analysis of randomized, controlled trials Ann Intern Med 130 1999 800 809
6. T.E. Warkentin, M.N. Levine, J. Hirsh Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin N Engl J Med 332 1995 1330 1335
7. G. Pezzuoli, G.G. Neri Serneri, P. Settembrini Prophylaxis of fatal pulmonary embolism in general surgery using low-molecular weight heparin Cy 216: a multicentre, double-blind, randomized, controlled, clinical trial versus placebo (STEP) STEP-Study Group Int Surg 74 1989 205 210
8. M.T. Nurmohamed, F.R. Rosendaal, H.R. Buller Low molecular weight heparin versus standard heparin in general and orthopaedic surgery: a meta-analysis Lancet 340 1992 152 156
9. T.J. Rabelink, J.J. Zwaginga, H.A. Koomans, J.J. Sixma Thrombosis and hemostasis in renal disease Kidney Int 46 1994 287 296
10. M.J. Kovacs, C. Kearon, M.A. Rodger Single-arm study of bridging therapy with low-molecular-weight heparin for patients at risk of arterial embolism who require temporary interruption of warfarin Circulation 110 2004 1658 1663
11. K.R. Polkinghorne, L.P. McMahon, G.J. Becker Pharmacokinetic studies of dalteparin (Fragmin), enoxaparin (Clexane), and danaparoid sodium (Orgaran) in stable chronic hemodialysis patients Am J Kidney Dis 40 2002 990 995
12. H. Lord, N. Jean, M. Dumont, J. Kassis, M. Leblanc Comparison between tinzaparin and standard heparin for chronic hemodialysis in a Canadian center Am J Nephrol 22 2002 58 66
13. J. Hirsh, K.A. Bauer, M.B. Donati, M. Gould, M.M. Samama, J.I. Weitz Parenteral anticoagulants: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th edition) Chest 133 2008 141S 159S
14. B. Boneu, P. de Moerloose How and when to monitor a patient treated with low molecular weight heparin Semin Thromb Hemost 27 2001 519 522
15. J.W. Hainer, J.S. Barrett, C.A. Assaid Dosing in heavy-weight/obese patients with the LMWH, tinzaparin: a pharmacodynamic study Thromb Haemost 87 2002 817 823
16. P. Schmid, A.G. Fischer, W.A. Wuillemin Prevalence of impaired renal function in medical inpatients Swiss Med Wkly 137 2007 514
17. M.N. Levine, A. Planes, J. Hirsh, M. Goodyear, N. Vochelle, M. Gent The relationship between anti-factor Xa level and clinical outcome in patients receiving enoxaparine low molecular weight heparin to prevent deep vein thrombosis after hip replacement Thromb Haemost 62 1989 940 944
18. A. Leizorovicz, L. Bara, M.M. Samama, M.C. Haugh Factor Xa inhibition: correlation between the plasma levels of anti-Xa activity and occurrence of thrombosis and haemorrhage Haemostasis 23 suppl 1 1993 89 98
19. R.C. Becker, F.A. Spencer, M. Gibson Influence of patient characteristics and renal function on factor Xa inhibition pharmacokinetics and pharmacodynamics after enoxaparin administration in non-ST-segment elevation acute coronary syndromes Am Heart J 143 2002 753 759
20. W. Lim, F. Dentali, J.W. Eikelboom, M.A. Crowther Meta-analysis: low-molecular-weight heparin and bleeding in patients with severe renal insufficiency Ann Intern Med 144 2006 673 684
21. W. Lim, D.J. Cook, M.A. Crowther Safety and efficacy of low molecular weight heparins for hemodialysis in patients with end-stage renal failure: a meta-analysis of randomized trials J Am Soc Nephrol 15 2004 3192 3206
22. B. Ljungberg, S.H. Jacobson, L.E. Lins, G. Pejler Effective anticoagulation by a low molecular weight heparin (Fragmin) in hemodialysis with a highly permeable polysulfone membrane Clin Nephrol 38 1992 97 100
23. G.R. Hetzel, C. Sucker The heparins: all a nephrologist should know Nephrol Dial Transplant 20 2005 2036 2042
24. J.W. Hainer, D.J. Sherrard, S.K. Swan Intravenous and subcutaneous weight-based dosing of the low molecular weight heparin tinzaparin (Innohep) in end-stage renal disease patients undergoing chronic hemodialysis Am J Kidney Dis 40 2002 531 538
25. S.L. Perry, S.I. O'shea, S. Byrne, L.A. Szczech, T.L. Ortel A multi-dose pharmacokinetic study of dalteparin in haemodialysis patients Thromb Haemost 96 2006 750 755
26. I. Mahe, M. Aghassarian, L. Drouet Tinzaparin and enoxaparin given at prophylactic dose for eight days in medical elderly patients with impaired renal function: a comparative pharmacokinetic study Thromb Haemost 97 2007 581 586
27. E. Tincani, C. Mannucci, B. Casolari Safety of dalteparin for the prophylaxis of venous thromboembolism in elderly medical patients with renal insufficiency: a pilot study Haematologica 91 2006 976 979
28. P. Schmid, D. Brodmann, A.G. Fischer, W.A. Wuillemin Study of bioaccumulation of dalteparin at a prophylactic dose in patients with various degrees of impaired renal function J Thromb Haemost 7 2009 552 558
29. D. Cook, J. Douketis, M. Meade Venous thromboembolism and bleeding in critically ill patients with severe renal insufficiency receiving dalteparin thromboprophylaxis: prevalence, incidence and risk factors Crit Care 12 2008 R32
30. J. Nagge, M. Crowther, J. Hirsh Is impaired renal function a contraindication to the use of low-molecular-weight heparin? Arch Intern Med 162 2002 2605 2609
31. D.F. Brophy, E.J. Martin, A.M. Best, T.W. Gehr, M.E. Carr Antifactor Xa activity correlates to thrombin generation time, platelet contractile force and clot elastic modulus following ex vivo enoxaparin exposure in patients with and without renal dysfunction J Thromb Haemost 2 2004 1299 1304
32. D.F. Brophy, M.E. Carr Jr, E.J. Martin, J. Venitz, T.W. Gehr The pharmacokinetics of enoxaparin do not correlate with its pharmacodynamic effect in patients receiving dialysis therapies J Clin Pharmacol 46 2006 887 894